MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics, Inc. (QNCX)

|||

Cash Flow Overview

Change in Cash
$97,818K
Free Cash flow
-$18,887K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance of series...
    • Acquired in-process research and...
    • Stock based compensation
    • Others
Negative Cash Flow Breakdown
    • Accrued expenses and other curre...
    • Change in fair value of warrants
    • Gain on orphai acquisition
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-75,488
35,912
-39,458
-13,442
Stock based compensation
12,093
1,286
1,191
1,255
Depreciation and amortization
41
36
39
36
Change in the fair value of contingent consideration liabilities
0
-64,330
3,117
2,066
Change in fair value of debt, net
0
-12,197
491
490
Change in fair value of warrants
-4,507
-31,116
17,297
-291
Gain on settlement of accounts payable
1,136
2,584
-
-
Intangible asset impairment charge
0
67,808
-
-
Non-cash goodwill impairment charge
-
-
0
0
Acquired in-process research and development from the orphai acquistion
59,000
-
-
-
Reclassification of cumulative translation adjustment to net income
-
-
477
-
Gain on orphai acquisition
1,305
-
-
-
Amortization of discount on available-for-sale investments
0
62
188
236
Change in deferred tax liabilities
-
-
4,963
-
Prepaid expenses and other current assets
-362
3,639
-2,743
374
Right of use assets, operating leases and operating lease liabilities
-423
-28
-24
-27
Other assets
8
-1,782
-4,811
486
Accounts payable
260
5,911
-1,154
1,631
Accrued expenses and other current liabilities
-7,934
-7,163
5,304
-604
Other liabilities
-688
701
742
-
Net cash used in operating activities
-18,887
-7,627
-10,481
-9,928
Purchase of investments
0
0
4,922
15,707
Proceeds from maturities of investments
0
12,000
12,997
14,000
Purchase of property and equipment
0
0
4
74
Net cash assumed in the orphai acquisition
-8,001
-
-
-
Net cash provided by investing activities
8,001
12,000
8,071
-1,781
Payment of contingent consideration
-
-
0
0
Proceeds from issuance of common stock upon exercise of stock options
0
0
37
0
Proceeds from issuance of common stock, common warrants, and pre-funded warrants pursuant to june 2025 private placement offering, net of issuance costs
0
-
0
0
Proceeds from issuance of series c preferred stock and financing warrants pursuant to may 2026 private placement offering, net of issuance costs
103,639
-
-
-
Issuance of common stock in connection with the atm offerings, net of issuance costs
5,350
14,988
1,997
1,376
Repayment of debt
0
5,545
-
-
Cash settlement of common warrants
56
-
-
-
Net cash provided by financing activities
108,933
9,443
2,034
1,376
Effect of exchange rate changes on cash
-229
-1,462
-267
-41
Net increase in cash and cash equivalents
97,818
12,354
-643
-10,374
Cash and cash equivalents at beginning of period
18,163
5,809
6,452
6,212
Cash and cash equivalents at end of period
115,981
18,163
5,809
6,452
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofseries c preferred...$103,639K Issuance of common stockin connection with...$5,350K (85.12%↑ Y/Y)Net cash assumed inthe orphai...-$8,001K Net cash provided byfinancing activities$108,933K (651.31%↑ Y/Y)Net cash provided byinvesting activities$8,001K (-52.76%↓ Y/Y)Canceled cashflow$56K Net increase in cashand cash...$97,818K (821.59%↑ Y/Y)Canceled cashflow$19,116K Cash settlement ofcommon warrants$56K Acquired in-processresearch and development...$59,000K Stock basedcompensation$12,093K (354.80%↑ Y/Y)Right of use assets,operating leases and...-$423K (-698.11%↓ Y/Y)Prepaid expenses andother current assets-$362K (38.44%↑ Y/Y)Accounts payable$260K (118.35%↑ Y/Y)Depreciation andamortization$41K (-38.81%↓ Y/Y)Net cash used inoperating activities-$18,887K (10.13%↑ Y/Y)Effect of exchange ratechanges on cash-$229K (-218.04%↓ Y/Y)Canceled cashflow$72,179K Net income (loss)-$75,488K (-142.89%↓ Y/Y)Accrued expenses andother current...-$7,934K (-837.36%↓ Y/Y)Change in fair value ofwarrants-$4,507K (-200.96%↓ Y/Y)Gain on orphaiacquisition$1,305K Gain on settlement ofaccounts payable$1,136K Other liabilities-$688K Other assets$8K (-93.39%↓ Y/Y)